Mounjaro 5.0mg: the first therapeutic dose explained

What the SURMOUNT trial data actually shows at this dose

The pivotal SURMOUNT-1 trial randomised 2,539 adults with obesity across three tirzepatide dose groups: 5mg, 10mg and 15mg. After 72 weeks, participants on 5mg lost an average of around 15–16% of their body weight. That is a clinically significant result on its own, roughly comparable to the average seen with semaglutide 2.4mg in the STEP 1 trial. The jump to 10mg and 15mg pushed average losses higher still, which is why titration continues for most people. But if you want to understand what the evidence says about staying at this level, our 5.0 tirzepatide page covers what the data shows for people who remain on this dose long term. For individuals who cannot tolerate higher doses, it remains a licensed maintenance option.

NICE, in its appraisal of tirzepatide (TA1026), noted that if less than 5% weight loss is achieved after six months at the highest tolerated dose, continuing treatment should be reviewed. The emphasis on highest tolerated is important: 5mg can be a person's ceiling if side effects at greater doses are unacceptable. That is a conversation for a prescriber, not a self-assessment.

One thing the trial data makes plain: results at every dose improve when treatment runs alongside a reduced-calorie diet and increased physical activity. Tirzepatide is licensed as an adjunct to lifestyle change, not a substitute for it. You can read more about the broader tirzepatide evidence base on our tirzepatide overview.

Why the 5mg pen is different from the 2.5mg starter

The 2.5mg dose has one job: settling your system into the medicine. Nausea and other GI effects are most likely when the body first encounters a GLP-1 or dual-agonist drug, and starting low reduces the chance of those effects being severe enough to make someone stop treatment. Once that four-week window passes, the prescriber moves you up.

At 5mg, the dual GIP and GLP-1 receptor activation begins to produce a meaningful suppression of appetite and a measurable slowdown in how quickly food leaves the stomach. Hunger signals arrive less frequently; satiety comes sooner during a meal. Blood-sugar regulation also improves, which is why tirzepatide carries a separate licence for type 2 diabetes alongside its weight-management indication.

The pen format is identical to the 2.5mg version, a pre-filled KwikPen, one injection per week into the abdomen, thigh or upper arm, rotated each time. Storage is the same: refrigerated at 2–8°C. For the exact room-temperature window if you need to travel with it, the Mounjaro patient information leaflet (available via the eMC) is the definitive reference; the figure is not one to quote from memory.

Curious about how this pen sits within the full dose ladder? Our Mounjaro treatment page covers the complete schedule from 2.5mg through to 15mg.

Side effects to expect when stepping up to 5mg

The most commonly reported effects at this dose are gastrointestinal: nausea, softer stools or diarrhoea, constipation, indigestion and burping. Fatigue and mild headache are also reported. These tend to peak in the first few days after the first 5mg injection, the body is adjusting again, much as it did at week one of 2.5mg, and for most people the effects settle within one to two weeks.

The NHS medicines page for tirzepatide lists what requires urgent medical attention: severe and persistent stomach pain that spreads to the back (a potential indicator of pancreatitis), symptoms of a gallbladder problem, or signs of a serious allergic reaction. None of these are common, but knowing them matters. If you experience them, contact a healthcare professional promptly, do not wait for your next scheduled review.

For a closer look at one of the less-discussed reported effects at this dose, our page on Mounjaro and eye floaters covers what the evidence does and does not show. And if you're looking for practical ways to manage tolerance as you step up, these tips from our clinical team are worth reading before your next injection.

Who reaches 5mg and what happens next

Most people starting tirzepatide through a regulated private prescriber will move to 5mg around week five of treatment, assuming the 2.5mg pen has been tolerated. The prescriber reviews your progress (weight change, side-effect profile, any relevant health changes) before each dose increase. That review is not automatic. It is a clinical assessment, and the outcome shapes whether titration continues.

For context on eligibility: tirzepatide is licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. Meeting the licence criteria does not bypass the prescriber's judgement on dosing.

If you arrived here after being prescribed Mounjaro privately and want to understand your treatment better, our guide to getting Mounjaro through a regulated UK pharmacy explains the process in full. When you're ready to talk to a prescriber about where your dose goes from here, start a free consultation with our team.